In the News

413 News Items found
Dana Pe'er and Scott Lowe
New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.
Lucy Kalanithi gestures while speaking. Physicians in white lab coats look on.
Support
Read a Q & A with Lucy Kalanithi, the widow of Paul Kalanithi, who wrote When Breath Becomes Air.
Rob with his wife and daughter
Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.
Dana Pe'er
Read an interview with Sloan Kettering Institute Computational and Systems Biology Chair Dana Pe'er.
Pictured: Johanna Joyce
In the Lab
A new study sheds light on what enables breast cancer cells to spread to the brain and presents a potential target for drugs.
Attendees of the fifth annual MSK-CTONG Symposium
Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou, China and New York on December 2, 2022.
a doctor and patient review a scan
Wasting — called cachexia — affects about half of all cancer patients. An MSK analysis of clinical data from more than 60,000 cancer patients is shedding new light on the condition.
MSK physician-scientist Yu Chen
The findings could pave the way toward more targeted treatments for the disease.
Proximal tubule of the kidney.
In the Lab
Memorial Sloan Kettering scientists have engineered a tiny particle that could ferry drugs directly to the kidneys and prevent their uptake in other organs.
A new therapy tested in mouse models appears to harness neutrophils, a type of white blood cell, to effectively prevent the spread of breast cancer cells.